◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2522

Jiangxi Rimag Group Co., Ltd. (2522) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Care Facilities · DATA UPDATED 2026-08-10

Jiangxi Rimag Group Co., Ltd. (2522) operates in the Medical Care Facilities industry and is headquartered in Beijing, China with about 1,406 employees. Its market capitalization is roughly CNY 2 billion. In the fiscal year ended 2025-12-31, 2522 reported CNY 873M in revenue and CNY 4M in net income.

Jiangxi Rimag Group Co., Ltd., together with its subsidiaries, invests in and operates medical imaging centers in Mainland China, Hong Kong, Macau, and internationally. It operates through Imaging Center Services, Imaging Solution Services, and Digital-Intelligent Services segments.

Interactive charts & full statements →

2522 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 873MCNY 761MCNY 929MCNY 784M
Gross ProfitCNY 295MCNY 277MCNY 333MCNY 237M
Operating Income (EBIT)CNY 50M(CNY 14M)CNY 80MCNY 43M
Net IncomeCNY 4M(CNY 46M)CNY 44MCNY 0M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2522 Free Cash Flow History

2522 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 2.9BCNY 2.3BCNY 1.9BCNY 2.0B
Total LiabilitiesCNY 854MCNY 780MCNY 544MCNY 673M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2522 viewer.

Other Companies in Medical Care Facilities

← 2521All “0-9” companies2525 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.